로딩 중…
지수 로딩 중…
Shaperon Inc.
378800· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩1,295+7.92%
2026-06-19
Price Chart
Shaperon Inc.-53.42%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 59.88B KRW |
| Revenue | 281.4M KRW |
| Net Income | -15.54B KRW |
| Total Assets | 24.70B KRW |
| Net Assets | 21.20B KRW |
| Employees | 54 |
| Value | |
| P/B | 2.82x |
| P/S | 212.81x |
| FCF Yield | -24.26% |
| Profitability | |
| ROE | -73.31% |
| ROA | -62.94% |
| Op. Margin | -5640.75% |
| Revenue Growth | 454.10% |
| Financial Health | |
| Debt Ratio | 116.48% |
| Total Debt | 60.8M KRW |
| FCF | -14.53B KRW |
| Cash | 1.07B KRW |
| Current Ratio | 9.30x |
| Performance | |
| 1Y Return | -53.42% |
| 1M Return | -3.07% |
| From 52W High | -61.80% |
| 1Y MDD | -70.88% |
| Trading | |
| Volume | 3,936,888 shares |
| Foreign Own. | 2.65% |
| Per Share | |
| EPS | -405 KRW |
| BPS | 458 KRW |
Company Info
SHAPERON, established in 2008 and listed on KOSDAQ in 2022, is a bio-venture company specializing in new drug candidate development. It expanded its global presence by establishing a U.S. subsidiary in 2023. The company possesses the world's first GPCR19 target-based inflammation inhibitor platform and a nanobody antibody development platform, with various therapeutics in clinical development. SHAPERON is accelerating new drug candidate discovery through an AI-based platform, established after its innovative new drug research center in 2023, and is headquartered in Gangnam-gu, Seoul.